MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
- MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decades
- MC2-25 CKD uses a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skin
- MC2-25 CKD has the potential to become the world’s first approved treatment for pre-dialysis Chronic Kidney Disease-associated Pruritus (CKD-aP), a debilitating condition thought to affect a significant proportion of the ~800 million people globally who suffer from Chronic Kidney Disease (CKD)
- 111 patients enrolled in the multi-center trial across Europe with topline results expected in Q2 2024
Copenhagen, December 7th, 2023 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory conditions, today announced it has completed enrollment in its European Phase 2 trial assessing the safety and efficacy of MC2-25 CKD, an innovative new drug candidate for the treatment of urea associated skin diseases, incl. CKD-aP Stage 5 (dialysis) and stages 3 and 4 (pre-dialysis), the latter segment having no approved treatment options.
MC2-25 CKD presents a potential breakthrough in the understanding and treatment of urea associated skin diseases that has puzzled scientists for decades. It is a totally novel treatment paradigm based on a di-peptide selected to inhibit carbamylation of amino acids and proteins in skin, which is believed to be the causal factor in CKD-aP. MC2-25 CKD has an attractive treatment profile based on convenience and tolerability and has the potential to provide relief from both the severe skin dryness and the debilitating itch associated with CKD-aP, which negatively impacts the quality of life of a significant proportion of the ~800 million people globally who suffer from CKD stages 3-5.
The Phase 2 clinical trial is being conducted at multiple centers across Europe and is evaluating the safety and efficacy of MC2-25 CKD in patients with CKD-aP stages 3-5. 111 patients have been enrolled in the study and randomized in a double-blinded, placebo-controlled parallel-group trial to 12 weeks topical treatment with MC2-25 CKD or placebo.
Top line results from the study are expected in Q2 2024. MC2-25 is also being evaluated in a Phase 2a PoC trial in Vulvar Lichen Sclerosis.
Jesper L. Lange, CEO of MC2 Therapeutics said: “There is increasing evidence that carbamylation plays a central role in various urea associated skin diseases. We are pioneering new ground in this important field and strongly believe that MC2-25 CKD has the potential to finally bring meaningful change to the millions of CKD patients who suffer from debilitating itch and dryness of their skin. We look forward to the data next year and to completing our discussions with regulatory authorities to fast track this treatment to patients globally.”
Kieran McCafferty, MD, at Barts Health NHS Trust and Senior Lecturer at Queen Mary University London and principal investigator of the trial, added: “CKD-aP is a frequent, and highly debilitating symptom of many patients with advanced CKD, a progressive condition which affects around 10% of the general population. This new understanding of the role played by carbamylation in CKD-aP is very exciting and offers hope to millions of patients.”
About MC2-25 CKD
The active component of MC2-25 CKD is a di-peptide, which is formulated in cream based on MC2 Therapeutics’ proprietary formulation and drug delivery system: PAD Technology™. It is an effective isocyanate scavenger showing >90 % inhibition of protein carbamylation and counteracts the morphological skin changes induced by carbamylation as demonstrated in an in vitro reconstructed human uremic skin model.
Isocyanate is in equilibrium with urea and it is a very reactive molecule known both to be neurotoxic and to readily react with proteins, peptides and amino acids present in the body and skin. In CKD patients, carbamylation of amino acids and proteins is highly upregulated and believed to be a key contributor to the root cause of CKD-aP.
About the MC2-25 CKD-aP Ph2 Trial
The trial is a Phase 2, randomized, multicenter, double-blinded, parallel-group trial in subjects with CKD-aP stages 3-5. The trial has enrolled 111 patients in multiple centers in Europe. Patients will apply the trial medication topically twice daily for 12 weeks.
The primary objective is to compare therapeutic efficacy of MC2-25 CKD compared to MC2-25 CKD vehicle and characterize the safety profile of MC2-25 CKD in subjects with CKD-aP stages 3-5. The primary efficacy endpoint is the mean change in weekly mean Worst Itch Numeric Rating Score (WI-NRS) from baseline to week 12. Secondary endpoints will be assessed, incl. treatment success according to responder endpoints, as well as various other patient and physician reported outcomes. Topline results are expected in Q2 2024.
CKD-aP affects a significant portion of the ~800 million people globally suffering from CKD. The vast majority of patients (90%) are pre-dialysis (stages 3 and 4) who currently have no approved treatment options. People suffering from CKD-aP have severe dry skin and evidence of damaged nerve fibers in the skin. CKD-aP is a debilitating condition, which negatively impacts quality of life leading to higher rates of depression and an increased mortality risk.
About MC2 Therapeutics
MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory diseases.
Its pioneering approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking. Fuelled by an entrepreneurial mindset and agility, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with immune-mediated and inflammatory conditions.
For additional information on MC2 Therapeutics, please visit www.mc2therapeutics.com.
Lonni Goltermann, +45 2018 1111, firstname.lastname@example.org
Media: ICR Consilium
Amber Fennell, +44 20 3709 5700, MC2@consilium-comms.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ensurge Micropower ASA - Registration of Share Capital Increase26.2.2024 12:15:41 CET | Press release
Oslo, 26 February 2024 Reference is made to the announcement by Ensurge Micropower ASA (the "Company") on 20 February 2024 regarding a successful private placement of shares ("Private Placement"), through an allocation of 233,468,885 new shares for total gross proceeds of NOK 58,367,221.25. The share capital increase has now been duly registered in the Register of Business Enterprises. Following the share capital increase, the Company's share capital is NOK 269,315,774.30 divided into 2,693,157,743 shares, each share having a par value of NOK 0.10. About Ensurge Micropower: Ensurge is Energizing Innovation (TM) with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1 to 100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense rechargeable products that are ideal for form-factor-constrained applications including hearables (hearing aids and wireless
Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme26.2.2024 12:10:00 CET | Press release
Company Announcement No. 10/2024 Copenhagen, 26 February 2024 Transactions in connection with share buy-back programme On 10 November 2023, Scandinavian Tobacco Group A/S announced that a share buy-back programme of an aggregated value of up to DKK 850 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. Part of the programme will be conducted in accordance with Regulation No. 596/2014 of the Euro-pean Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Another part of the share buy-back programme is conducted as a directed buy-back from Chr. Augustinus Fabrikker Aktieselskab and C.W. Obel A/S as further described in company announcement no. 30/2023. The share buy-back programme will end no later than 28 February 2025. The following transactions have been executed from
Novo Nordisk A/S - share repurchase programme26.2.2024 12:02:48 CET | Press release
Bagsværd, Denmark, 26 February 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2023. Under the programme initiated 6 February 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 6 February 2024 to 30 April 2024. Since the announcement 19 February 2024, the following transactions have been made: Number of B sharesAverage purchase priceTransaction value, DKKAccumulated, last announcement394,500327,673,06019 February 202442,500855.9136,376,12820 February 202443,000855.3936,781,82921 February 202443,000829.8435,683,11022 February 202443,000848.4136,481,7
Calibre Intercepts High Grade Gold Mineralization at the Limon Mine Complex, Proximal to the Limon Processing Plant; Drilling Intersects Include 68.72 g/t Gold Over 2.0 Metres and 18.68 g/t Gold Over 6.0 Metres26.2.2024 12:00:05 CET | Press release
VANCOUVER, British Columbia, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (the "Company" or "Calibre") is pleased to announce exciting drill results from its 2023 resource expansion and infill program at the Tigra, Limon Norte and Pozo Bono open pit deposits located next to the Limon processing plant. These high-grade intercepts combined with the recent positive news from the Panteon VTEM Gold Corridor, demonstrate that the entire Limon district remains open for expansion and discovery. Drill intercept highlights from the Tigra, Limon Norte and Pozo Bono targets include: 68.72 g/t Au over 2.0 metres Estimated True Width (“ETW”) and 16.49 g/t Au over 5.9 metres ETW including 26.71 g/t Au over 3.5 metres ETW in Hole LIM-23-4875;18.68 g/t Au over 5.9 metres ETW including 55.68 g/t Au over 2.0 metres ETW in Hole LIM-23-4876;9.26 g/t Au over 5.0 metres ETW including 17.10 g/t Au over 2.6 metres ETW in Hole LIM-23-4858;12.85 g/t Au over 4.2 metres ETW inclu
Cargotec announces positive results from the written procedures for its senior unsecured notes due 2025 and 202626.2.2024 12:00:00 CET | Press release
CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 26 FEBRUARY 2024 AT 1:00 P.M. (EET) Cargotec announces positive results from the written procedures for its senior unsecured notes due 2025 and 2026 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON LOCATED OR RESIDENT IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SOUTH AFRICA, JAPAN, NEW ZEALAND OR SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. THIS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR BUY ANY OF THE SECURITIES DESCRIBED HEREIN. Cargotec Corporation (“Cargotec”) announced on 8 February 2024 the commencement of the written procedures (the “Written Procedures”) and approached the holders of its EUR 100,000,000 1.250 per cent senior unsecured notes due 2025 (ISIN: FI4000399688) (the “2025 Notes”) and EUR 150,000,000 1.625 per cent senior unsecured notes due 2026 (ISIN: FI4000399696) (